ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
AbbVie Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$282.68−2.74 (-0.96%)
Close on Oct 19, 2026
- Market cap
- $500.63B
- P/E (TTM)
- 79.9
- Dividend yield
- 2.35%
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
70.2%+3.8 pts over 5 years
Operating margin
24.6%−0.2 pts over 5 years
Net margin
6.9%−3.2 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +8.6% | +1.8% | +6.0% | +10.3% | |
| Gross profit | +8.9% | +1.9% | +7.1% | +8.9% | |
| Operating income | +65.0% | -5.9% | +5.8% | +7.2% | |
| Net income | -1.2% | -29.1% | -1.7% | -1.9% | |
| EPS, diluted | -1.3% | -29.1% | -2.8% | -2.8% | |
| Free cash flow | -0.1% | -9.8% | +1.2% | +9.8% | |
| Dividend per share | +5.7% | +5.2% | +6.6% | +12.2% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 138.7% | 188.3% | 15367.3% | |
| Return on assets | 10.0% | 3.9% | 3.1% | |
| Current ratio | 1.65 | 0.84 | 0.67 | |
| Debt to equity | 7.95 | 6.58 | -20.64 | |
| Interest coverage | 8.9× | 4.6× | 5.2× | |
| Inventory turnover | 3.7× | 6.0× | 4.0× | |
| Capex to revenue | 1.9% | 1.7% | 2.0% | |
| Diluted shares | 1.63B | 1.67B | 1.77B |
Where the cash went
Fiscal 2021 to 2025, five years combined
AbbVie generated $108.40B from operations and spent $64.05B on capital expenditure, dividends and share buybacks. 7% of that went back into the business.
Generated
$108.40B
Used
$64.05B
Capital expenditure$4.45B7%Dividends$52.53B82%Share buybacks$7.08B11%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin6.9%
×Asset turnover0.45×
×Equity multiplier4893.11×
=Return on equity, FY202515367.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 6.9% | 0.45× | 4893.11× | 15367.3% |
| FY2024 | 7.6% | 0.42× | 19.72× | 62.5% |
| FY2023 | 9.0% | 0.40× | 9.90× | 35.2% |
| FY2022 | 20.4% | 0.41× | 8.74× | 72.5% |
| FY2021 | 20.5% | 0.38× | 10.43× | 81.0% |
| FY2020 | 10.1% | 0.38× | 48.87× | 188.3% |
| FY2019 | 23.7% | 0.45× | -8.93× | -94.9% |
| FY2018 | 17.4% | 0.50× | -38.86× | -339.6% |
| FY2017 | 18.8% | 0.41× | 14.06× | 109.1% |
| FY2016 | 23.2% | 0.43× | 13.89× | 138.7% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
8of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$4.23B
- Cash generatingOperating cash flow above zero$19.03B
- Return on assets improvedROA up on the prior year3.2% → 3.1%
- Earnings backed by cashOperating cash flow above net income$19.03B vs $4.23B
- Less leverageLong-term debt to assets fell44.6% → 44.0%
- Better liquidityCurrent ratio rose0.66 → 0.67
- No dilutionShare count did not rise1.77B → 1.77B
- Gross margin improvedGross margin up on the prior year69.99% → 70.24%
- More efficientAsset turnover rose0.42 → 0.45